Join collection
Hello, welcome to our official website!
腾讯立志成为移动互联网“连接器”
2019-01-12

马化腾公开致信合作伙伴:腾讯立志成为移动互联网“连接器”


11月1日,腾讯将在南京举办2018腾讯全球合作伙伴大会。在开幕前夕,腾讯董事会主席兼**执行官马化腾发表了《给合作伙伴的一封信》,向合作伙伴分享了关于消费互联网与产业互联网生态融合、社交与内容生态创新的思考,并提出了腾讯在移动互联网下半场的开放战略新目标。

他认为,伴随数字化进程,移动互联网的主战场,正在从上半场的消费互联网,向下半场的产业互联网方向发展。要让个人用户获得更好的产品与服务,就必须让互联网与各行各业深度融合。腾讯也非常愿意成为各行各业*好的“数字化助手”,以“去中心化”的方式帮助传统企业和公共服务机构实现数字化转型升级,

未来与企业和政府等机构客户的合作中,腾讯的业务接口将更加集中,合作规则更加清晰,资源能力更形成合力。腾讯将更充分地发挥数字化服务潜能和差异化优势:不但要能够提供基础工具和能力的“食材”;还要能快速响应个性化需求,将不同食材搭配起来“炒菜”;更要提供一整套的“宴席”——多样化、系统化、安全可控的商业解决方案(BaaS, 即Business as a Service)。

此外,马化腾也表示,腾讯也将进一步打造年轻人喜欢的社交平台与内容生态,与数字内容领域的合作伙伴建立更加紧密的新生态;借助“社交×内容”的网络效应,通过新文创的方式让更多用户和年轻人,获得高品质的数字内容消费体验,并以*先进的技术手段保护好未成年人,避免不健康的消费沉迷。

在移动互联网下半场,腾讯开放战略也将树立新目标。马化腾表示,腾讯要做好“连接器”,为各行各业进入“数字世界”提供*丰富的“数字接口”;还要做好“工具箱”,提供*完备的“数字工具”;更要做好“生态共建者”,提供云计算、大数据和人工智能等新型基础设施,激发每个参与者进行数字创新,与各行各业合作伙伴一起共建“数字生态共同体”。

“腾讯并不是要到各行各业的跑道上去赛跑争**,而是要立足做好‘助手’,帮助实体产业在各自的赛道上成长出更多的世界**。”马化腾表示。

以下为公开信全文:

各位合作伙伴,大家好!

今年是腾讯成立20年周年。我们迎来了公司历史上的第三次重大战略升级和架构调整。这个消息已经在一个月前公布。在这里,我想跟各位合作伙伴分享更多的想法。

这次调整,我们经过了将近一年的思考和酝酿。腾讯自2012年以来组建的七大事业群,目前已经重组为六大事业群。在保留原有的技术工程事业群(TEG)、微信事业群(WXG)、互动娱乐事业群(IEG)、企业发展事业群(CDG)基础上,我们整合成立了两个新的事业群:云与智慧产业事业群(CSIG)、平台与内容事业群(PCG)。同时,我们整合升级了新的广告营销服务线,并将成立腾讯技术委员会。腾讯每隔六七年就可能进行一次大的组织架构调整,以顺应外界变化带来的战略升级。今天,我们两个新成立的BG,分别承担着消费互联网与产业互联网生态融合、社交与内容生态创新的重要探索。

我们认为,移动互联网的上半场已经接近尾声,下半场的序幕正在拉开。伴随数字化进程,移动互联网的主战场,正在从上半场的消费互联网,向下半场的产业互联网方向发展。腾讯一直说专注做连接,希望连接人与人、人与物以及人与服务。我们越来越发现,除了实现人与人的连接,如果大量的“物”与“服务”不能全面数字化升级,那么“人与物、人与服务的连接”就难以迭代。要让个人用户获得更好的产品与服务,我们必须让互联网与各行各业深度融合,把数字创新下沉到生产制造的核心地带,将数字化推进到供应链的每一个环节。没有产业互联网支撑的消费互联网,只会是一个空中楼阁。

接下来,腾讯将扎根消费互联网,拥抱产业互联网。我们要继续做好“消费端”的智慧连接,更要促成“供应端”与互联网的深度融合,帮助各行各业实现数字化转型升级。对于大量的传统企业来说,要尽快打通从生产制造到消费服务的价值链,要实现从智慧零售到智能制造、从消费到产业(C2B)的生态协同,就不能仅仅满足于一个完整的传统产业链,未来更需要与互联网公司进行跨界融合,真正触达海量用户,并实现硬件、软件与服务三位一体的生态化能力。没有消费互联网助力的产业互联网,就像一条无法与大海连通的河流,可能在沙漠中日渐干涸。

腾讯服务着数以十亿计的个人用户,具有连接国内*丰富场景和互联网产品的生态服务能力,将致力于消费互联网与产业互联网的融合创新。我们非常愿意成为各行各业*好的“数字化助手”,以“去中心化”的方式帮助传统企业和公共服务机构实现数字化转型升级,让每一个产业都变身为智慧产业,实现数字化、网络化和智能化。

从2011年起,腾讯的开放战略伴随着移动互联网的高速发展而不断演进。七年时间,我们从“一棵大树”成长为“一片森林”,与合作伙伴共建了一个开放的互联网生态,可以说,我们在移动互联网上半场基本实现了开放战略的目标。接下来,我们要做好“连接器”,为各行各业进入“数字世界”提供*丰富的“数字接口”;还要做好“工具箱”,提供*完备的“数字工具”;同时我们更要做好“生态共建者”,提供云计算、大数据和人工智能等新型基础设施,激发每个参与者进行数字创新,与各行各业合作伙伴一起共建“数字生态共同体”。这是腾讯开放战略在移动互联网下半场希望实现的新目标。

产业互联网的探索,将为我们与生态伙伴提供更广阔的合作空间。我们希望,未来与企业和政府等机构客户的合作中,腾讯的业务接口更加集中,合作规则更加清晰,资源能力更能形成合力。腾讯将把数字化服务的潜能和差异化优势,更充分地发挥出来:我们不但能够根据客户的需要提供基础工具和能力作为“食材”;还能够快速响应客户的个性化需求,将不同食材搭配起来“炒菜”;更重要的是,我们还能够提供一整套的“宴席”——多样化、系统化、安全可控的商业解决方案(BaaS, 即Business as a Service)。这不单单能够帮客户节省成本、提**率,而且还能够帮助客户在数字化转型升级过程中,找到新的商业模式和盈利增长点。目前我们已经在医疗、教育、交通、零售和制造业等领域进行初步尝试。

与此同时,我们希望进一步打造年轻人喜欢的社交平台和内容生态,与数字内容领域的合作伙伴建立更加紧密的新生态。我们将借助“社交×内容”的网络效应,让UGC与PGC彼此滋养,形成*有活力的IP创生土壤。我们还希望与合作伙伴一起,帮助更多优秀的IP获得跨平台、多形态的发展机会,通过新文创的方式让更多用户和年轻人,获得高品质的数字内容消费体验,并以*先进的技术手段保护好未成年人,避免不健康的消费沉迷。

我们将更加重视科技驱动力。几天前,我受邀在知乎提问,非常高兴看到很多网友针对基础科学的突破、产业互联网与消费互联网的融合创新,做了相当精彩的回答。过去,中国互联网与科技行业的创新,往往是“应用需求找技术支持”。未来,我相信会有越来越多创新来自“技术突破寻求产品落地”。腾讯正在不断引入各领域的优秀科学家,也希望通过加大基础科学投入、建立公司技术委员会等措施,尽可能为科研工作者和技术人员创造更好的工作氛围和团队文化,真正让“科技创新”与“数字工匠精神”成为更多人追求的方向。

我们有理由期待,数字时代能够实现工业时代难以达到的工艺水平,创造出更高品质、更为独特的产品与服务。当然,腾讯并不是要到各行各业的跑道上去赛跑争**,而是要立足做好“助手”,帮助实体产业在各自的赛道上成长出更多的世界**。

过去一年,我们看到很多用户与合作伙伴通过各种渠道对腾讯的发展提出了意见和建议。在此,我要向关心腾讯发展的每一位朋友道一声感谢。你们的期待和鼓励,是腾讯多年来不断迭代进步的重要动力。

希望我们一起携手努力!谢谢大家!

2018年10月31日

转自腾讯科技

暂无评论!
我要评论 只有购买过该商品的用户才能评论。

Major Chinese biopharmaceutical company Hansoh Pharmaceutical Group Company Limited (Hanmori Pharmaceutical Group Co., Ltd., Hanso Pharmaceutical) and AI ) Atomwise, Inc., a leader in the field, announced the collaboration. The purpose of the collaboration is to design and discover potential drug candidates for a total of 11 private target proteins in multiple therapeutic areas.Atomwise and Hansoh Pharma scientific teams work closely together in each program. The combination of complementary expertise and technology has the potential to dramatically increase success rates and shorten schedules in drug discovery and clinical development.Dr. Aifeng Lyu, President of Jiangsu Hansoh Pharmaceutical Group Co., Ltd., a subsidiary of Hansoh Pharma, said: “Atomwise is the best partner for Hansoh Pharma to use AI technology to innovate and create diverse small molecule pipelines in oncology and other therapeutic areas. I am very impressed with the team and I believe that working together will provide a special opportunity to develop first-in-class and best-in-class therapeutics. "Dr. Abraham Heifets, CEO of Atomwise, said: “It is a great pleasure for us to partner with Chinese biopharmaceutical giant Hansoh Pharma. Hansoh Pharma shares our strong commitment to innovation and our mission to influence patient health globally.”Atomwise's world-class AI platform for structure-based drug design leads the way in finding hit compounds, selecting lead compounds from hit compounds, and optimizing lead compounds. Hansoh Pharma will contribute in its capacity in biological assays and medicinal chemistry, and will lead the subsequent preclinical and clinical development.Subject to the terms of the collaboration, Atomwise will receive revenue based on private technology fees, option exercise fees, royalties, and sublicenses and sales of assets created under the collaboration. Based on historical average sales of small molecule drugs, the overall potential value of this transaction for Atomwise may exceed the potential value of a hit drug if all projects succeed. Hansoh Pharma receives development and commercialization rights in all fields and regions.2019 Asia-pacific pharma IP Leader Summit: http://en.zenseegroup.com/p/404716/ will be held in Beijing  on November 14-15, and will attract more than 500 industry experts from domestic and foreign pharmaceutical companies, biotechnology companies, governments, associations, law firms, intellectual property agents and other companies to attend.Official registration and consultation channels:Contact:AnnPhone: 021-65650305Email:Marketing@zenseegroup.comhttp://www.zenseegroup.com/forms/view/22113/

Akari Therapeutics, Plc, a biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and inflammatory diseases where the complement (C5) and/or leukotriene (LTB4) systems are implicated, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation for nomacopan for the treatment of bullous pemphigoid (BP).“BP, a severe blistering skin condition with no approved treatments, is an exciting therapeutic target for our lead drug candidate, nomacopan. It is also a disease of increasing prevalence due to an aging population and improving diagnosis,” said Clive Richardson, Chief Executive Officer of Akari Therapeutics. “Orphan drug designation for nomacopan is a major step forward for the program, positioning nomacopan for eligibility for an additional seven years of marketing exclusivity in BP if nomacopan is approved by the FDA. This news is in addition to the recent orphan drug designation received for our HSCT-TMA program.”The Company plans to release new safety and efficacy data from an ongoing Phase II trial with nomacopan in patients with BP at an oral presentation by Dr. Christian Sadik at the 28th European Academy of Dermatology and Venereology (EADV) Congress on October 10, 2019. In August, the Company announced new data demonstrating the synergistic benefits of nomacopan’s dual C5 and LTB4 inhibitory activity in pemphigoid disease, generated by Dr. Christian Sadik’s group at University of Lubeck, Germany, and published in the August 2019 edition of JCI Insight [link].Orphan drug designation by the FDA is granted to promote the development of drugs that target conditions affecting 200,000 or fewer U.S. patients annually and that are expected to provide significant therapeutic advantage over existing treatments. Orphan designation qualifies Akari for various benefits, including seven years of market exclusivity following marketing approval, tax credits on U.S. clinical trials, eligibility for orphan drug grants, and a waiver of certain administrative fees.2019 Asia-pacific pharma IP Leader Summit: http://en.zenseegroup.com/p/404716/ will be held in Beijing  on November 14-15, and will attract more than 500 industry experts from domestic and foreign pharmaceutical companies, biotechnology companies, governments, associations, law firms, intellectual property agents and other companies to attend.Official registration and consultation channels:Contact:AnnPhone: 021-65650305Email:Marketing@zenseegroup.comhttp://www.zenseegroup.com/forms/view/22113/

China's leading biopharmaceutical company Hansoh Pharmaceutical Group Company Limited (" Hansen Pharmaceutical ") and drug discovery artificial intelligence (AI) Atomwise, Inc. (" Atomwise ") , a leader in the field, announced a collaborative design and discovery of potential drug candidates for up to 11 unexposed target proteins in a variety of therapeutic areas.Atomwise and Hansen Pharmaceutical's scientific team will work closely together in these projects. The combination of complementary expertise and technology is expected to significantly increase success and reduce timelines for drug discovery and clinical development.Dr. Lu Aifeng, President of Jiangsu Hansoh Pharmaceutical Group Co., Ltd., said: Hansen Pharmaceutical is committed to using AI technology to innovate and develop diverse small molecules in the field of cancer and other therapeutics. Atomwise is the right partner for Hansen Pharmaceuticals. We are very impressed with Atomwise's AI platform, capabilities and team. We believe that the two companies will have an excellent opportunity to develop similar and best-in-class therapeutic drugs. ."Dr. Abraham Heifets, CEO of Atomwise, said: "We are very excited to work with Hansen Pharmaceutical, China's leading biopharmaceutical company. Hansen Pharmaceuticals and we all have strong commitment to innovation and a common mission to influence the health of patients worldwide. ."The world-class AI platform for Atomwise structured drug design will guide efforts in hit discovery, accidental discovery to hit-to-lead selection, and optimization of lead compounds. Hansen Pharmaceuticals is committed to biological testing and pharmaceutical chemistry, as well as leading subsequent preclinical and clinical development activities.Under the terms of the partnership, Atomwise will receive undisclosed technology royalties, optional royalties, royalties, and subcontracting authorizations or revenue generated from the sale of the derivative assets. Based on the historical average turnover of small molecule drugs, the potential total value of all successful projects with Atomwise's transaction may exceed potential selling drugs. Hanson Pharmaceuticals will receive development and commercialization rights in all fields and geographies.2019 Asia-pacific pharma IP Leader Summit: http://en.zenseegroup.com/p/404716/ will be held in Beijing  on November 14-15, and will attract more than 500 industry experts from domestic and foreign pharmaceutical companies, biotechnology companies, governments, associations, law firms, intellectual property agents and other companies to attend.Official registration and consultation channels:Contact:AnnPhone: 021-65650305Email:Marketing@zenseegroup.comhttp://www.zenseegroup.com/forms/view/22113/

WEDNESDAY, SEPTEMBER 11, 2019I-Mab Biopharma (I-Mab), a China and U.S.-based clinical stage biopharmaceutical company exclusively focused on the discovery and development of potential first-in-class and best-in-class biologics in immuno-oncology and autoimmune diseases announces the signing of a collaboration agreement with Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences), an innovation-driven biopharmaceutical company to evaluate the combination therapy of I-Mab's TJD5, a proprietary innovative CD73 antibody with Junshi Biosciences' Toripalimab (Trade name: Tuoyi), a recombinant humanized anti-PD-1 monoclonal antibody in patients with cancers in China.Dr. Jingwu Zang, Founder and Chairman of I-Mab, commented, "TJD5 is an innovative CD73 antibody with best-in-class potential that has entered into Phase I trial in the US. We are very pleased to collaborate with Junshi to explore the clinical synergies with Toripalimab which is an innovative drug with distinctive treatment advantages. We are looking forward to bringing more clinical benefits to patients across various cancer types."Dr. Ning Li, CEO of Junshi Biosciences, commented, "As an anti multi-tumor drug, toripalimab has shown good safety and efficacy in clinical trials with mono and combination therapy. We believe, through the cooperation with I-Mab, we could continue to explore the combination potential of toripalimab and innovative drugs to improve the outcomes of immune-oncology therapy, lightening hope for more patients.2019 Asia-pacific pharma IP Leader Summit: http://en.zenseegroup.com/p/404716/ will be held in Beijing  on November 14-15, and will attract more than 500 industry experts from domestic and foreign pharmaceutical companies, biotechnology companies, governments, associations, law firms, intellectual property agents and other companies to attend.Official registration and consultation channels:Contact:AnnPhone: 021-65650305Email:Marketing@zenseegroup.comhttp://www.zenseegroup.com/forms/view/22113/

TUESDAY, SEPTEMBER 10, 2019ProBioGen AG, a premier service and technology provider for complex therapeutic antibodies and glycoproteins, today announced the closing of a license agreement with Bayer AG for the  GlymaxX® Technology. Under the terms of the agreement, Bayer will leverage the technology to further increase the potency of an undisclosed antibody candidate for oncological indications.ProBioGen’s proven antibody-dependent cellular cytotoxicity (ADCC) enhancing technology GlymaxX® will be applied during cell line development.“We are glad to add Bayer to our list of licensees”, says ProBioGen’s Chief Executive Officer Dr. Wieland Wolf. “The GlymaxX® technology is clinically proven and is a very flexible technology which is liked by all cell lines.”About ProBioGen AGProBioGen is a premier, Berlin-based specialist for developing and manufacturing complex therapeutic antibodies and glycoproteins. Combining both state-of-the-art development services, based on ProBioGen’s CHO.RiGHT™ expression and manufacturing platform, together with intelligent product-specific technologies yields biologics with optimized properties.Rapid and integrated cell line and process development, comprehensive analytical development and following reliable GMP manufacturing is performed by a highly skilled and experienced team.All services and technologies are embedded in a total quality management system to assure compliance with international ISO and GMP standards (EMA/FDA).ProBioGen was founded 1994, is privately owned, and located in Berlin, Germany.About GlymaxX®The GlymaxX® technology, developed by ProBioGen, prevents the cellular synthesis of the sugar “fucose” and hence, in antibody-producing cells, its addition to the N-linked carbohydrate part of the antibody. The absence of fucose is known to greatly enhance ADCC. The GlymaxX® technology is based on the stable introduction of a gene for an enzyme which blocks the producer cells’ fucose biosynthesis pathway. As a unique feature, differentiating it from other approaches, GlymaxX® can be applied to both novel or already existing antibody producer cell lines, and entire antibody expression and discovery platforms, without negatively affecting their productivity or other product characteristics.Furthermore, a single GlymaxX® cell line can be flexibly used to produce differently fucosylated products, depending on the upstream process: In fucose-free medium the antibody is quantitatively afucosylated. The same GlymaxX® cell line grown in fucose-containing medium however, uses the provided fucose and produces fully fucosylated antibody. Thus, a GlymaxX® cell line can by employed to produce different products: For instance ADCC-enhanced GlymaxX® antibodies or wildtype-like, fully fucosylated mAbs, for a parallel Antibody-Drug-Conjugate (ADC) project.Finally, GlymaxX® has been used by biosimilar-developing companies to adjust a specific content of fucose in order to match the originators glycoprofile. Overall, GlymaxX® is simple, rapid, potent, and universally applicable to different CHO hosts and all other eukaryotic cell species.ProBioGen offers its GlymaxX® technology royalty-free and non-exclusively as a service or as an individual license.2019 Asia-pacific pharma IP Leader Summit: http://en.zenseegroup.com/p/404716/ will be held in Beijing  on November 14-15, and will attract more than 500 industry experts from domestic and foreign pharmaceutical companies, biotechnology companies, governments, associations, law firms, intellectual property agents and other companies to attend.Official registration and consultation channels:Contact:AnnPhone: 021-65650305Email:Marketing@zenseegroup.comhttp://www.zenseegroup.com/forms/view/22113/

About Us
Contact Us
Zensee_Daystar online